David R. Margrave

CIK: 0001813162

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (60.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (40.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

LTRN

Lantern Pharma Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

LTRN
Lantern Pharma Inc.
Dec 18, 2025
Award(A)
Stock Option (Right to Buy)
Direct
20K shares-
LTRN
Lantern Pharma Inc.
Oct 29, 2021
Disposition(D)
Stock Option (Right to Buy)
Direct
26.1K shares-
LTRN
Lantern Pharma Inc.
Oct 29, 2021
Award(A)
Stock Option (Right to Buy)
Direct
26.1K shares-
LTRN
Lantern Pharma Inc.
Jun 15, 2020
Disposition(D)
Stock Option (Right to Buy)
Direct
78.3K shares-
LTRN
Lantern Pharma Inc.
Jun 15, 2020
Award(A)
Stock Option (Right to Buy)
Direct
78.3K shares-

		Type	Shares	Price		Ownership
Dec 18, 2025	LTRN Lantern Pharma Inc.	Award(A) Stock Option (Right to Buy)	20,000	-	-	Direct
Oct 29, 2021	LTRN Lantern Pharma Inc.	Disposition(D) Stock Option (Right to Buy)	26,100	-	-	Direct
Oct 29, 2021	LTRN Lantern Pharma Inc.	Award(A) Stock Option (Right to Buy)	26,100	-	-	Direct
Jun 15, 2020	LTRN Lantern Pharma Inc.	Disposition(D) Stock Option (Right to Buy)	78,300	-	-	Direct
Jun 15, 2020	LTRN Lantern Pharma Inc.	Award(A) Stock Option (Right to Buy)	78,300	-	-	Direct

1-5 of 5 transactions

About Margrave David R.

Margrave David R. (SEC CIK 0001813162) files insider reports with the SEC as Chief Financial Officer of Lantern Pharma Inc. (LTRN).

Signal8 holds 2 ownership filings by Margrave David R., all Form 4s, filed between Sep 23, 2025 and Dec 22, 2025. Those filings report 5 transactions, from Jun 15, 2020 to Dec 18, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Margrave David R.'s filings is in DALLAS, TX.

Recent filings by Margrave David R.

Dec 18, 2025: Grant or award of LTRN derivative securities (Form 4, code A).
Oct 29, 2021: Disposition to issuer transaction of LTRN derivative securities (Form 4, code D).
Oct 29, 2021: Grant or award of LTRN derivative securities (Form 4, code A).
Jun 15, 2020: Disposition to issuer transaction of LTRN derivative securities (Form 4, code D).
Jun 15, 2020: Grant or award of LTRN derivative securities (Form 4, code A).

Other insiders filing for Lantern Pharma Inc. (LTRN)

Schalop Lee Troy, Director
KEYSER D JEFFREY, Director
Maccecchini Maria-Luisa, Director
Chandru Vijay, Director
Silberstein David S., Director
Bhatia Kishor G., Chief Scientific Officer

How to read Form 4 transaction codes